Compare DexCom, Inc. (DXCM) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs IONQ Inc — how do they compare? DexCom, Inc. trades at $90.63 (market cap $33.79B), while IONQ Inc trades at $45.09 (market cap $17.60B). The key difference: DexCom, Inc. is the larger of the two by market cap, and DexCom, Inc. is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | IONQ | |
|---|---|---|
Market Cap | $33.79B | $17.60B |
Sector | Health | Technology |
52-Week High | $89.53 | $82.09 |
52-Week Low | $54.84 | $26.59 |
Enterprise Value | $33.24B | $15.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.
Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
